SCIENTIFIC STUDY REPORT
|
|
- Edgar Dean
- 5 years ago
- Views:
Transcription
1 PAGE 1 18-NOV-2016 SCIENTIFIC STUDY REPORT Study Title: Real-Life Effectiveness and Care Patterns of Diabetes Management The RECAP-DM Study 1 EXECUTIVE SUMMARY Introduction: Despite the well-established association between elevated haemoglobin A1C (HbA1C) levels and increased risks of microvascular and macrovascular complications in patients with type 2 diabetes mellitus (T2DM), evidence suggests that the majority of T2DM patients are not at HbA1C goal according to recommendations of consensus treatment panels. This study was undertaken to assess the level of glycemic control in real life practice settings in patients with T2DM.who had been treated with metformin monotherapy and initiated combination therapy with either a sulfonylurea or a glitazone three years prior to study enrolment, according to treatment goals recommended by national and international clinical practice guidelines in seven European countries. Methods: This was an observational, cross-sectional multicenter study with retrospective medical chart review conducted in Finland, France, Germany, Norway, Poland, Spain and UK. Included in the study were T2DM patients with a healthcare provider visit during an enrolment period between June 2006 to February 2007 who had added a SU or a TZD to metformin monotherapy between January 2001 and January 2006 (i.e. index date) and who had at least one hemoglobin A1C (HbA1C) measurement within 12 months before the visit date. Case report forms were used to collect demographic and clinical information from medical charts. The key study outcome was the proportion of patients with adequate glycemic control (defined according to the International Diabetes Federation as HbA1C < 6.5%) using the most recent HbA1C measurement before the visit date.
2 PAGE 2 18-NOV-2016 Key Results For the 2023 patients that met inclusion/exclusion criteria, mean age at the index date was 60.4 years, 45.3% were female, 1.5% had a history of microvascular complications, and 24.0% had a history of macrovascular complications of diabetes. The mean HbA1C level was 8.1%, and 92.7% of patients were not at HbA1C goal prior to the index date. Following addition of either an SU or a TZD, the mean HbA1C was 7.2% with 25.5% of patients being at HbA1C goal based on the most recenthba1c measurement before the visit date. For the rest of the patients 49.0% had HbA1C between 6.5% and 7.6%, while 25.6% of patients had HbA1C values greater than 7.6%. Relative to those not at goal, patients at HbA1C goal had significantly (p < 0.05) lower HbA1C (7.6% vs. 8.2%) prior to index date, were less likely to report a history of macrovascular complications (20% vs. 26%) and were more likely to report physical activity three to five times a week (29% vs. 23%). Key Conclusions In this study of T2DM patients from seven European countries, approximately one quarter were at HbA1C goal. The findings are in line with prior studies documenting that in general patients with T2DM are not treated to consensus HbA1C targets. 2 VALUE TO THE FRANCHISE THE STUDY DEMONSTRATES THE SIGNIFICANT UNMET NEED AMONG T2DM PATIENTS. THE STUDY HIGHLIGHTS THE NEED OF IMPROVING CARE MANAGEMENT IN DIABETES AS WELL AS OF DEVELOPING NEW AND EFFECTIVE THERAPEUTIC AGENTS. EM recommendations for use of the platform The study demonstrates that T2DM is a progressive disease with poor glycemic control even after treatment intensification. The path to better glycemic control would include better patient engagement and adherence to therapy, enhanced provider involvement in care management, and improved medications.
3 PAGE 3 18-NOV INTRODUCTION The association between elevated hemoglobin A1C (HbA1C) levels and increased risks of microvascular and macrovascular complications in patients with type 2 diabetes mellitus (T2DM) is well established. With the aim of improving overall outcomes among T2DM patients, consensus treatment panels have set aggressive HbA1C targets spurred on by clinical findings and epidemiologic studies. However, evidence suggests that the majority of T2DM patients are not at HbA1C goal according to recommendations of consensus treatment panels. This has been reported even after treatment intensification with insulin. This study was undertaken to assess the level of glycemic control in real life practice settings in patients with T2DM.who had been treated with metformin monotherapy and initiated combination therapy with either a sulfonylurea or a glitazone three years prior to study enrolment, according to treatment goals recommended by national and international clinical practice guidelines in seven European countries. The study contributes in the literature by employing a consistent methodology in assessing glycemic control across countries in patients who were treated with combination oral antihyperglycemic agents as a result of inadequate glycemic control on metformin monotherapy. 4 METHODS The Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study was an observational, cross-sectional multicenter study involving patients with T2DM receiving oral antihyperglycemic treatment in Finland, France, Germany, Norway, Poland, Spain and UK. Included in the study were T2DM patients identified from medical charts at participating endocrinology, diabetology and general practice clinics. Study centers were selected randomly from a list comprising a convenience sample of physicians from each country. Eligible patients were identified during an enrollment period between June 2006 and February Identified patients were required to be at least 30 years old, to have added a SU or a TZD to metformin monotherapy between January 2001 and January 2006 (i.e. index date) and to have at least one hemoglobin A1C (HbA1C) measurement within 12 months before the visit date. Excluded were patients with T1DM; pregnant women, including those with gestational diabetes; diabetes secondary to other factors (e.g., malnutrition, infection, surgery); and those who could not complete questionnaires or were participating in another clinical study. Participating patients were asked to sign an informed-consent form prior to enrollment. Both the informed-consent document and study protocol were reviewed and approved by local ethical review boards in each country. Case report forms were used to collect demographic and clinical information from medical charts such as age and sex, smoking status, alcohol use, physical activity, history of microvascular and cardiovascular events, time since diabetes diagnosis, and most recent HbA1C measurement within the year before the enrollment date. The key study outcome was the proportion of patients with adequate glycaemic control (defined according to the International Diabetes Federation as HbA1C < 6.5%) using the most recent HbA1C measurement before enrollment date.
4 PAGE 4 18-NOV OBJECTIVES REPORTED IN THIS MEMO Primary Objectives This study aimed to assess the level of glycemic control in real life practice settings in patients with type 2 diabetes who had been treated with metformin monotherapy and initiated combination therapy with either a sulfonylurea or a glitazone three years prior to study enrolment, according to treatment goals recommended by national and international clinical practice guidelines 6 RESULTS Demographics A total of 2,023 patients met the inclusion and exclusion criteria and participated in the study. The mean patient age was 60.4 years, and the mean body mass index was 31.8 kg/m2 (Table 1). Among all patients, 1.5% had a history of microvascular complications, and 24.0% had a history of macrovascular complications of diabetes. DM was diagnosed for mean 5.8 years. The mean A1C level was 8.1%, and 7.3% of patients were at A1C goal (<6.5%). Patients who used insulin during follow-up (n = 243), compared with who did not (n = 1,780), had similar baseline demographic and clinical characteristics, except for lower rates of A1C at goal: 3.3% vs 7.8% (Table 1). Disposition Recruitment and Duration of Study A convenience sample of randomly selected physicians was derived from endocrinology, diabetology, and general-practice clinics and offices in Finland, France, Germany, Norway, Poland, Spain, and the United Kingdom. Eligible patients were identified for participation in the study from June 2006 to February Safety Results: None to Report
5 PAGE 5 18-NOV-2016 Detailed Results Following the addition of either SU or TZD to metformin monotherapy, the average most recently measured A1C level was 7.2%, and 25.5% of patients had reached A1C goal (i.e. <6.5%). Patients who had not received insulin during follow-up, compared with patients who did received insulin therapy, had lower A1C levels (7.1% vs 7.8%), and almost 3 times higher rate of reaching A1C goal (27.6% vs 9.5%). A1C level ranged from 7.1% in Poland to 7.3% in Norway and the United Kingdom. The rate of reaching A1C goal ranged from 15.6% in Norway to 30.1% in France. (Table 2) Patients who did not reach A1C goal, compared with those who did, had higher baseline rates of cardiovascular comorbidities, family history of cardiovascular conditions, and macrovascular conditions, and higher baseline rates of weight-reducing treatment and no other treatment (Table 3). There was also a slight trend of lower rates of goal attainment in patients receiving treatment for hypertension or dyslipidemia, and lower rates in patients who reported less physical activity 7 DISCUSSION Glycaemic control was poor overall, despite the prevalent use of combination oral antihyperglycaemic therapy with or without insulin, in this European cohort of patients with T2DM. The average A1C level at study completion was 7.2%, which exceeds the target goal of <6.5% recommended by IDF. Only 25.5% of patients had reached A1C goal of <6.5% (IDF). A1C goal attainment was lower in patients with more aggressive therapy, perhaps reflecting greater disease severity. Patients who failed to reach A1C goal at study completion had higher rates of use of combination treatment, including insulin and insulin use at follow-up. As expected, high-risk patients, with a history of macrovascular disease, hypertension, or dyslipidemia, tended to have less glycaemic control. Patients with a macrovascular condition at baseline had a significantly reduced chance of A1C goal attainment, after adjusting for covariates (OR 0.674). Physical activity was associated with glycaemic control, with lower rates of activity reported in patients who failed to attain A1C goal. Limitations of the study There are several potential study limitations inherent in the study design. Causality cannot be determined conclusively, due to the observational nature of the study. Results may potentially be confounded by the use of cardiovascular medications. Finally, the use of a convenience sample of physicians to recruit patients for the study may undermine the external validity of our findings.
6 PAGE 6 18-NOV-2016 Appendix 1 1. Details of Statistical Methods Patient demographics and survey responses were summarized using descriptive statistics. Differences in patient reports of hypoglycaemia and A1C goal status at visit date were evaluated by t-tests (continuous variables) or chi-square tests (categorical variables). Wald s test statistic was used to examine an association between hypoglycaemic symptom severity and A1C goal status at visit date. Statistical significance was evaluated at α = 0.05.
7 PAGE 7 18-NOV Supplemental analyses Table 1: Baseline demographic and clinical characteristics, overall and by insulin use during follow up* Characteristic Overall (N=2,023) No insulin used during follow up (n=1,780) Insulin used during follow up (n=243) Age, yr 60.4 ± ± ± 9.8 Percent female Current smoker % % % Never used alcohol % % % No regular physical activity % % % Physical activity % % % times/week Weight, kg 88.9 ± ± ± 20.3 Body mass index, kg/m ± ± ± 6.7 Age at DM diagnosis, yr 54.7 ± ± ± 9.6 Duration of DM at index date, 5.8 ± ± ± 5.1 yr Duration on metformin prior to 2.8 ± ± ± 2.6 index date, yr A1C 8.1 ± ± ± 1.6 Percent at A1C goal Fasting blood glucose, mg/dl ± ± ± 91.5 Family history of myocardial 19.4 % 18.8 % 23.7 % infarction Family history of DM 47.4 % 47.2 % 49.0 % Comorbid ischaemic heart 14.1 % 13.6 % 17.8 % disease Comorbid coronary heart failure 2.7 % 2.6 % 3.03 % Comorbid myocardial infarction 5.3 % 4.9 % 8.23 % Comorbid stroke 2.5 % 2.4 % 3.03 % Macrovascular conditions 24.0 % 23.4 % 28.1 % Microvascular conditions 1.5 % 1.4 % 2.2 % Hypotensive therapy 67.2 % 66.6 % 71.8 % Lipid-lowering therapy 47.6 % 47.6 % 47.9 % Weight-reducing therapy 1.8 % 1.6 % 3.0 % No other treatment 22.3 % 22.3 % 22.2 % Total cholesterol, mmol/l 5.2 ± ± ± 1.5 HDL cholesterol, mmol/l 1.3 ± ± ± 0.4 LDL cholesterol, mmol/l 3.0 ± ± ± 1.1 Triglyceride level, mmol/l 2.2 ± ± ± 2.3 Systolic blood pressure ± ± ± 17.6 Diastolic blood pressure 82.7 ± ± ± 9.9
8 PAGE 8 18-NOV-2016 DM, diabetes mellitus; HDL, high-density lipoprotein; LDL, low-density lipoprotein *Data are mean ± s.d. unless otherwise specified. A1C <6.5% as measured within 12 months prior to visit
9 PAGE 9 18-NOV-2016 Table 2: Change in A1C at study completion by country.* Current A1C level nearest study enrollment date, % A1C <6.5 at follow-up, % Duration from index date to current A1C, yr Duration with T2DM at A1C follow-up, yr Duration on OHA, yr Overall (N=2,023) 7.17 ± 1.14 No insulin used during follow up (n=1,780) 7.09 ± 1.09 Insulin used during follow up (n=243) 7.79 ± 1.31 Spain (n=493) 7.17 ± 1.25 France (n=169) 7.11 ± 1.01 UK (n=407) 7.30 ± 1.16 Norway (n=64) 7.34 ± 1.08 Finland (n=193) 7.18 ± 1.23 Germany (n=410) 7.12 ± 1.03 Poland (n = 293) ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± 3.06 T2DM, type 2 diabetes mellitus; OHA, oral antihyperglycaemic agents *Data are mean ± s.d.
10 PAGE NOV-2016 Table 3: Comparison of demographic and clinical characteristics of patients who attain A1C goal vs. those who do not attain A1C goal* Patients with A1C > 6.5% at follow up (n = 1,508) Patients with A1C < 6.5% at follow up (n = 515) Age at index date, yr 60.4 ± ± 10.2 Age at follow-up, yr 63.0 ± ± 10.3 Percent female 45.2 % 45.4 % Current smoker 13.9 % 11.0 % Never used alcohol 29.9 % 29.0 % No regular physical activity 37.7 % 30.2 % Physical activity 3-5 times/week 22.9 % 28.8 % Patient weight at baseline, kg 88.8 ± ± 18.9 Patient body mass index at baseline, kg/m ± ± 7.8 Age at DM diagnosis, yr 54.6 ± ± 10.1 Years with DM diagnosis at index date, yr 5.8 ± ± 4.6 Years on metformin prior to index date, yr 2.9 ± ± 2.6 A1C at baseline 8.2 ± ± 1.3 Percent at A1C goal at baseline 4.6 % 15.2 % Fasting blood glucose at baseline, mg/dl ± ± 83.2 Duration from index to current A1C measure 2.6 ± ± 1.4 Duration with T2DM at follow-up 8.4 ± ± 4.9 Duration on oral antihyperglycaemic agent 5.5 ± ± 3.0 Family history of myocardial infarction 20.6 % 15.8 % Family history of diabetes 47.5 % 47.1 % Comorbid ischaemic heart disease at baseline 15.8 % 9.3 % Comorbid coronary heart failure at baseline 3.0 % 1.6 % Comorbid myocardial infarction at baseline 5.9 % 3.6 % Comorbid stroke at baseline 2.4 % 2.6 % Macrovascular conditions at baseline 25.5 % 19.6 % Microvascular conditions at baseline 1.5 % 1.6 % Hypotensive treatment at baseline 68.3 % 64.0 % Lipid-lowering treatment at baseline 48.4 % 45.5 % Weight-reducing treatment at baseline 1.7 % 0.2 % No other treatment at baseline 21.9 % 2.4 % Total cholesterol at baseline in mmol/l 5.2 ± ± 1.3 HDL at baseline in mmol/l 1.3 ± ± 0.4 LDL at baseline in mmol/l 3.0 ± ± 11 Triglycerides at baseline in mmol/l 2.3 ± ± 1.8 Systolic blood pressure at baseline ± ± 16.8 Diastolic blood pressure at baseline 83.0 ± ± 9.8 *Data are mean ± s.d. unless otherwise specified. A1C <6.5% as measured within 12 months prior to visit
Clinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationThe effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes
The effect of insulin detemir in combination with liraglutide and metformin compared to liraglutide and metformin in subjects with type 2 diabetes This trial is conducted in Europe and North America. The
More informationEffectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care
University of Rhode Island DigitalCommons@URI Senior Honors Projects Honors Program at the University of Rhode Island 2009 Effectiveness of a Multidisciplinary Patient Assistance Program in Diabetes Care
More information(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects
Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values
More informationClinical Trial Synopsis TL-OPI-525, NCT#
Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationTUE Physician Guidelines Medical Information to Support the Decisions of TUE Committees Diabetes Mellitus DIABETES MELLITUS
DIABETES MELLITUS 1. Introduction Diabetes is a global epidemic with 415 million people affected worldwide equivalent to the total population of the USA, Canada and Mexico. In recognition of this, the
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationSponsor / Company: Sanofi Drug substance(s): Insulin Glargine. Study Identifiers: NCT
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationMeasure Owner Designation. AMA-PCPI is the measure owner. NCQA is the measure owner. QIP/CMS is the measure owner. AMA-NCQA is the measure owner
2011 EHR Measure Specifications The specifications listed in this document have been updated to reflect clinical practice guidelines and applicable health informatics standards that are the most current
More informationATHLETES & PRESCRIBING PHYSICIANS PLEASE READ
ATHLETES & PRESCRIBING PHYSICIANS PLEASE READ USADA can grant a Therapeutic Use Exemption (TUE) in compliance with the World Anti- Doping Agency International Standard for TUEs. The TUE application process
More informationDownloaded from:
Mamza, J; Mehta, R; Donnelly, R; Idris, I (2016) Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase- 4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary
More informationSponsor: Sanofi Drug substance(s): Lantus /insulin glargine. Study Identifiers: U , NCT Study code: LANTUL07225
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationClinialTrials.gov Identifier: HOE901_4020 Insulin Glargine Date: Study Code: This was a multicenter study that was conducted at 59 US sites
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMetabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study. Arab Medical University. Benghazi, Libya
Original Article Metabolic Syndrome among Type-2 Diabetic Patients in Benghazi- Libya: A pilot study Alshkri MM 1, Elmehdawi RR 2 1 Benghazi Diabetes Center. 2 Medical Department, Faculty of Medicine,
More informationAn estimated 20.8 million Americans 7% of the population
Provider Organization Performance Assessment Utilizing Diabetes Physician Recognition Program Bruce Wall, MD, MMM; Evelyn Chiao, PharmD; Craig A. Plauschinat, PharmD, MPH; Paul A. Miner, PharmD; James
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationModelling Reduction of Coronary Heart Disease Risk among people with Diabetes
Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Katherine Baldock Catherine Chittleborough Patrick Phillips Anne Taylor August 2007 Acknowledgements This project was made
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationInvestigators, study sites Multicenter, 35 US sites. Coordinating Investigator: Richard Bergenstal, MD
STUDY SYNOPSIS Study number Title HMR1964A/3502 Apidra (insulin glulisine) administered in a fixed-bolus regimen vs. variable-bolus regimen based on carbohydrate counting in adult subjects with type 2
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationKnow Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up
Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up... Study Population: 340... Total Population: 500... Time Window of Baseline: 09/01/13 to 12/20/13... Time Window of Follow-up:
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationLong-Term Cost-effectiveness of Saxagliptin for the Treatment of Type 2 Diabetes in South Africa
Long-Term Cost-effectiveness of Saxagliptin for the Treatment of Type 2 Diabetes in South Africa Deon Olivier October 2012 1 Introduction Saxagliptin is a DPP-4 inhibitor for the treatment of type 2 diabetes
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationStatistical Analysis Plan FINAL. DexComG4 (DexCom Corporation) CGMMDI GOLD-Study
1.0 Page 1 of 15 FINAL DexComG4 (DexCom Corporation) CGMMDI GOLD-Study monitoring (CGM) in individuals with type 1 diabetes treated 2016-07-07 Approvals Name/Title: Nils-Gunnar Pehrsson / Statistiska Konsultgruppen,
More informationESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study
ESM1 for Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: a retrospective cohort study Statistical modelling details We used Cox proportional-hazards
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationClinical and Economic Summary Report. for Employers
Clinical and Economic Summary Report for Employers Magaly Rodriguez de Bittner, PharmD, CDE, FAPhA Director, P 3 Program Dawn Shojai, PharmD Assistant Director, P 3 Program P 3 Clinical & Economic Summary
More informationEfficacy/pharmacodynamics: 85 Safety: 89
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:
More informationCME/CE QUIZ CME/CE QUESTIONS
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation The University of Cincinnati College of Medicine designates this educational activity for a maximum of two (2) AMA PRA Category 1
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationSYNOPSIS. Administration: subcutaneous injection Batch number(s):
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top
More informationData Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial
Data Analysis Plan for assessing clinical efficacy and safety of ER niacin/laropiprant in the HPS2-THRIVE trial 1 Background This Data Analysis Plan describes the strategy, rationale and statistical methods
More informationNOTICE. Release of final Health Canada document: Standards for Clinical Trials in Type 2 Diabetes in Canada
September 24, 2007 NOTICE Our file number: 07-122151-509 Release of final Health Canada document: Standards for Clinical Trials in Type 2 Diabetes in Canada The final version of the Health Canada guidance
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationStatin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography
Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,
More informationType 2 diabetes is one of the most common
Q Manage Health Care Vol. 15, No. 1, pp. 58 65 c 2006 Lippincott Williams & Wilkins, Inc. The Need for Quality Management in Primary Health Care in Cyprus: Results From a Medical Audit for Patients With
More information4. resisted training ** OR resistance training * OR resisted exercise ** OR resistance exercise ** OR strength training ** OR strength exercise **
Supplementary Table 1. Search strategy (up to January 10 th 2015). MEDLINE Result: 253 studies 1. clinical trial ** OR controlled trial ** OR randomized controlled trial * OR randomised controlled trial
More informationDIABETES MEASURES GROUP OVERVIEW
2014 PQRS OPTIONS F MEASURES GROUPS: DIABETES MEASURES GROUP OVERVIEW 2014 PQRS MEASURES IN DIABETES MEASURES GROUP: #1. Diabetes: Hemoglobin A1c Poor Control #2. Diabetes: Low Density Lipoprotein (LDL-C)
More informationSMJ Singapore Medical Journal
SMJ Singapore Medical Journal ONLINE FIRST PUBLICATION Online first papers have undergone full scientific review and copyediting, but have not been typeset or proofread. To cite this article, use the DOIs
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationStudy Code: Date: 27 July 2007
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationEyes on Korean Data: Lipid Management in Korean DM Patients
Eyes on Korean Data: Lipid Management in Korean DM Patients ICDM Luncheon Symposium Sung Rae Kim MD PhD Division of Endocrinology and Metabolism The Catholic University of Korea Causes of Death in People
More informationDiabetes Overview. How Food is Digested
Diabetes Overview You are The Teacher, The Coach and the Fan Pathophysiology of Diabetes Complications Know the Numbers Treatment Can Good Control Make a Difference? Can Tight Control Be too Tight? How
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationType 2 diabetes in Tuvalu: A drug use and chronic disease management evaluation. Prepared for the Ministry of Health, Tuvalu.
Type 2 diabetes in Tuvalu: A drug use and chronic disease management evaluation Prepared for the Ministry of Health, Tuvalu. 2012 Investigator Alexander Bongers Intern pharmacist, Royal Melbourne Hospital,
More informationIndividualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus
1 Dissertation Title Page: Individualized Treatment Goals for Optimal Long-Term Health Outcomes among Patients with Type 2 Diabetes Mellitus Qian Shi, MPH, PhD candidate Department of Global Health Management
More informationTUEC Guidelines Medical Information to Support the Decisions of TUE Committees Diabetes Mellitus DIABETES MELLITUS
DIABETES MELLITUS 1. Introduction Diabetes is a global epidemic with 415 million people affected worldwide equivalent to the total population of the USA, Canada and Mexico. In recognition of this, the
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationThe prevalence and morbidity associated with type 2. Review
Review Annals of Internal Medicine Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus Shari Bolen, MD, MPH; Leonard Feldman, MD; Jason Vassy, MD, MPH;
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationPEER REVIEW HISTORY ARTICLE DETAILS TITLE (PROVISIONAL)
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to
More informationClinical Therapeutics/Volume 33, Number 1, 2011
Clinical Therapeutics/Volume 33, Number 1, 2011 Concurrent Control of Blood Glucose, Body Mass, and Blood Pressure in Patients With Type 2 Diabetes: An Analysis of Data From Electronic Medical Records
More informationSerum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic
Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li
More information(a) y = 1.0x + 0.0; r = ; N = 60 (b) y = 1.0x + 0.0; r = ; N = Lot 1, Li-heparin whole blood, HbA1c (%)
cobas b system - performance evaluation Study report from a multicenter evaluation of the new cobas b system for the measurement of HbAc and lipid panel Introduction The new cobas b system provides a point-of-care
More informationDiabetes Control and Complications in Public Hospitals in Malaysia
ORIGINAL ARTICLE Diabetes Control and Complications in Public Hospitals in Malaysia Mafauzy M. FRCP For the Diabcare-Malaysia Study Group, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian,
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationImpact of Physical Activity on Metabolic Change in Type 2 Diabetes Mellitus Patients
2012 International Conference on Life Science and Engineering IPCBEE vol.45 (2012) (2012) IACSIT Press, Singapore DOI: 10.7763/IPCBEE. 2012. V45. 14 Impact of Physical Activity on Metabolic Change in Type
More informationDiabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions
Diabetes and Concomitant Cardiovascular Disease: Guideline Recommendations and Future Directions Diabetes is one of the largest global health emergencies of 21 st century, with the number of people with
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationBEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS
BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS Neil R Poulter ICCH, Imperial College London BHIVA: October 10th, 2008 Background CVD is the biggest single killer in the world CVD rates are increasing High
More informationAmerican Academy of Insurance Medicine
American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker
More informationSupplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationBariatric Surgery versus Intensive Medical Therapy for Diabetes 3-Year Outcomes
The new england journal of medicine original article Bariatric Surgery versus Intensive Medical for Diabetes 3-Year Outcomes Philip R. Schauer, M.D., Deepak L. Bhatt, M.D., M.P.H., John P. Kirwan, Ph.D.,
More informationIntercommunale de Santé Publique du Pays de Charleroi, Charleroi, Belgium 2
Lipid Abnormalities Remain High among Treated Hypertensive Patients with Stable CHD: Results of the Dyslipidemia International Study (DYSIS) II Belgium Michel Guillaume 1, Eric Weber 2, Johan De Sutter
More informationInternational Journal of Research in Pharmacology & Pharmacotherapeutics
344 International Journal of Research in Pharmacology & Pharmacotherapeutics Available online at Print ISSN: 2278 2648 Online ISSN: 2278-2656 IJRPP Volume 2 Issue 2 2013 Research article Study on Rational
More informationGUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES
GUIDELINES FOR DYSLIPIDEMIA MANAGEMENT AND EDUCATION THROUGH NOVA SCOTIA DIABETES CENTRES Prepared by DCPNS Action Committee Dr. Lynne Harrigan Brenda Cook Peggy Dunbar Bev Harpell with the assistance
More informationDIABETES WORKSHOP EMEA Improved treatments : medication for children/adolescents with diabetes mellitus
DIABETES WORKSHOP EMEA Improved treatments : medication for children/adolescents with diabetes mellitus Aim: to identify the best possible research approaches for new medication in the field of diabetes
More informationType 2 Diabetes in Adolescents
Type 2 Diabetes in Adolescents Disclosures Paid consultant, Eli Lilly, Inc, Pediatric Type 2 Diabetes Clinical Trials Outline The burden of diabetes Treatment and Prevention Youth Diabetes Prevention Clinic
More informationRISK FACTORS FOR DIABETIC RETINOPATHY PROGRESSION
2015 ILEX PUBLISHING HOUSE, Bucharest, Roumania http://www.jrdiabet.ro Rom J Diabetes Nutr Metab Dis. 22(2):159-165 doi: 10.1515/rjdnmd-2015-0020 RISK FACTORS FOR DIABETIC RETINOPATHY PROGRESSION Mónika
More information